Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
OBJECTIVE: Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients’ symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospita...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567197/ https://www.ncbi.nlm.nih.gov/pubmed/33102342 http://dx.doi.org/10.4103/jfmpc.jfmpc_1166_19 |